Summary

The global women’s health market was valued at USD 58,444.46 million in 2025 and is projected to reach USD 114,925.76 million by 2035. The market is expected to grow at a CAGR of 6.93% during the forecast period, driven by rising awareness of women-specific healthcare needs and increasing investments in advanced treatment solutions.

Rising Diagnosis and Early Detection of Gynaecological Disorders
Being diagnosed is just the beginning of treatment and management for women suffering from gynaecological issues such as endometriosis, fibroids, ovarian cysts, and cervical cancer, which are among the greatest inducers of the worldwide female health market. Partly, this increased demand has been due to awareness programs and other advanced means of diagnostics coupled with additional screening, which have given rise to the earlier detection and timely treatment of these conditions.

Segment-Wise Market Insights
By Product
- Contraceptive - Rising demand for family planning solutions.
- Fertility and Ovulation Induction Drugs - Increasing infertility cases driving treatment adoption.
- Vaginal and Uterine Products - Growing focus on gynecologically care products.
- Bone Health Agents - Higher osteoporosis prevalence supporting market growth.
- Pain and Symptom Management - Expanding use for menstrual pain relief.
- Others - Emerging therapies widening women’s healthcare applications.
By Therapeutic Area
- Reproductive Health and Fertility - Increasing reproductive health awareness among women.
- Menopause and Hormonal Disorders - Rising menopause management treatment demand globally.
- Gynaecological Disorders - Early diagnosis improving gynaecological treatment adoption rates.
- Others - Diverse healthcare applications supporting segment expansion.
By Age Group
- Below 30 - High contraceptive and reproductive healthcare demand.
- 31?40 - Fertility treatments witnessing increased adoption globally.
- 41?50 - Hormonal imbalance treatments gaining significant traction.
- Above 51 - Growing demand for menopause care therapies.
By Distribution Channel
- Retail Pharmacy - Easy accessibility boosting women’s health product sales.
- Hospital Pharmacy - Increasing hospital-based treatment and medication dispensing.
- Supermarket and Hypermarket - Convenient product availability supporting consumer purchases.
- Online Channels - E-commerce platforms driving digital healthcare accessibility.
- Others - Alternative distribution networks expanding product reach.

The global women's health market is dominated by the North American region due to the availability of modern healthcare facilities, larger healthcare expenditure, and digital health technologies. European countries, on the other hand, are benefiting from preventive healthcare programs and aged populations. Asia Pacific, however, is gaining ground as the most rapidly growing area as consumers become more healthcare aware, leading to better and more frequent usage of reproductive and maternal healthcare services.

Strategic Expansion in Molecular Imaging
On January 2026, Bayer AG expanded its precision cardiology portfolio by acquiring the investigational molecular imaging agents, AT-01 and AT-05, from Attralus. This acquisition helps Bayer increase its stake in the rapidly evolving molecular imaging market and at the same time, it is the first step in providing innovative diagnostic solutions for cardiac amyloidosis detection.

Expanding Demand for Safer Women’s Health Solutions
Transitioning away from hormone-based contraceptives and menopause therapies is a robust strategic opportunity in the global women's health market. Increasing education on the side effects of hormonal treatments has resulted in the desire for the adoption of non-hormonal contraceptives and more personalized and safer healthcare options.

Key Report Attributes
- Market Size 2025: USD 58,444.46 Million
- Market Size 2035: USD 114,925.76 Million
- CAGR (2025-2035): 6.93%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Product: Contraceptive - 6.77%, Fertility and Ovulation Induction Drugs - 8.24%.
- By Therapeutic Area: Reproductive Health and Fertility - 6.36%, Menopause and Hormonal Disorders - 7.87%.
- By Age Group: Below 30 - 6.62%, 31-40 - 7.86%.
- By Distribution Channel: Retail Pharmacy - 6.45%, Hospital Pharmacy - 5.91%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ........................................... 23
1.1 OVERVIEW .......................... 23
1.2 MARKET ATTRACTIVENESS ANALYSIS ......................... 24
1.3 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT ...... 25
1.4 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA ................................. 26
1.5 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP .............................................. 27
1.6 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL .......................... 28
1.7 GLOBAL WOMEN’S HEALTH MARKET, BY REGION ......... 29
2 MARKET INTRODUCTION ....................................... 31
2.1 DEFINITION ...................... 31
2.2 SCOPE OF THE STUDY ...... 31
2.3 RESEARCH OBJECTIVE ........... 31
2.4 MARKET STRUCTURE ........ 32
3 RESEARCH METHODOLOGY ................................. 33
3.1 OVERVIEW .......................... 33
3.2 DATA FLOW ........................ 35
3.2.1 DATA MINING PROCESS ...................................... 35
3.3 PURCHASED DATABASE: ........ 36
3.4 SECONDARY SOURCES: .......... 37
3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 38
3.5 PRIMARY RESEARCH: ............ 39
3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 40
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 41
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................ 42
3.6.1 REVENUE ANALYSIS APPROACH .......................... 42
3.7 DATA FORECASTING ............... 42
3.7.1 DATA FORECASTING TYPE ................................... 43
3.8 DATA MODELING .................. 44
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 44
3.8.2 DATA MODELING: ..... 45
3.9 TEAMS AND ANALYST CONTRIBUTION ................................... 47
4 MARKET DYNAMICS ............................................... 49
4.1 INTRODUCTION ................ 49
4.2 DRIVERS ............................. 50
4.2.1 RISING CONTRACEPTIVE USE .............................. 50
4.2.2 INCREASING INFERTILITY .................................... 50
4.2.3 AGING FEMALE POPULATION .............................. 51
4.2.4 RISING GYNECOLOGICAL DISORDERS ................... 51
4.3 RESTRAINTS ........................ 52
4.3.1 HORMONAL THERAPY SIDE EFFECTS ................... 52
4.3.2 CULTURAL STIGMA AND SOCIAL BARRIERS .......... 53
4.3.3 LIMITED HEALTHCARE ACCESS ........................... 53
4.4 OPPORTUNITIES ................... 54
4.4.1 RAPID EXPANSION OF FEMTECH AND DIGITAL HEALTH .................................. 54
4.4.2 DEVELOPMENT OF NON-HORMONAL THERAPIES ............................................ 55
5 MARKET FACTOR ANALYSIS ................................. 56
5.1 REGULATORY ENVIRONMENT & COMPLIANCE .......................... 56
5.2 TECHNOLOGICAL TRENDS & INNOVATION ............................... 57
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..................... 58
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 59
5.4.1 PRICING ANALYSIS .............................................. 59
5.4.1.1 NORTH AMERICA ..... 59
5.4.1.2 EUROPE ................. 59
5.4.1.3 ASIA PACIFIC ......... 59
5.4.1.4 LATIN AMERICA ...... 60
5.4.1.5 MIDDLE EAST & AFRICA ....................................... 60
5.4.2 REIMBURSEMENT DYNAMICS .............................. 60
5.5 MARKET ENTRY & EXIT BARRIERS .......................................... 62
5.5.1 BARRIERS TO ENTRY ........................................... 62
5.5.2 BARRIERS TO EXIT ............................................... 62
5.6 PARTNERSHIPS & COLLABORATIONS ...................................... 63
5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ............... 65
5.7.1 CONSUMER PREFERENCES .................................. 65
5.7.2 HEALTHCARE PROVIDER PREFERENCES ............... 65
5.8 PESTLE ANALYSIS ............ 65
5.8.1 POLITICAL FACTORS ........................................... 65
5.8.2 ECONOMIC FACTORS .......................................... 65
5.8.3 SOCIAL FACTORS ..... 66
5.8.4 TECHNOLOGICAL FACTORS ................................. 66
5.8.5 LEGAL FACTORS ...... 66
5.8.6 ENVIRONMENTAL FACTORS ................................ 66
5.9 PORTER'S FIVE FORCES MODEL ........................................... 67
5.9.1 THREAT OF NEW ENTRANTS ................................ 68
5.9.2 BARGAINING POWER OF SUPPLIERS .................... 68
5.9.3 BARGAINING POWER OF BUYERS ......................... 68
5.9.4 THREAT OF SUBSTITUTES ................................... 68
5.9.5 INTENSITY OF RIVALRY ....................................... 68
5.10 PRODUCT PIPELINE ANALYSIS ............................................. 69
5.11 CASE STUDY ANALYSIS ......... 70
5.12 INVESTMENT & FUNDING SCENARIOS ................................... 71
5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ........................ 72
5.14 DISEASE OVERVIEW .............. 73
5.15 DIAGNOSIS ......................... 74
5.16 CURRENT TREATMENT ..... 75
6 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT ................................... 78
6.1 OVERVIEW .......................... 78
7 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA ................. 82
7.1 OVERVIEW .......................... 82
8 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP ............................... 84
8.1 OVERVIEW .......................... 84
9 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL.......... 86
9.1 OVERVIEW .......................... 86
10 GLOBAL WOMEN’S HEALTH MARKET, BY REGION ....................................... 89
10.1 OVERVIEW .......................... 89
10.2 NORTH AMERICA .................. 91
10.2.1 US ........................... 97
10.2.2 CANADA .................. 101
10.3 EUROPE ............................. 105
10.3.1 GERMANY ................ 111
10.3.2 UK ........................... 115
10.3.3 FRANCE ................... 119
10.3.4 NETHERLANDS ......... 123
10.3.5 ITALY ....................... 127
10.3.6 SPAIN ...................... 131
10.3.7 REST OF EUROPE ...... 135
10.4 ASIA-PACIFIC ................... 139
10.4.1 CHINA ...................... 145
10.4.2 INDIA ....................... 149
10.4.3 JAPAN ..................... 153
10.4.4 SOUTH KOREA .......... 156
10.4.5 MALAYSIA ............... 159
10.4.6 THAILAND ................ 162
10.4.7 INDONESIA .............. 165
10.4.8 REST OF APAC ......... 168
10.5 LATIN AMERICA ................... 172
10.5.1 BRAZIL ..................... 177
10.5.2 MEXICO ................... 180
10.5.3 ARGENTINA ............. 183
10.5.4 REST OF LATIN AMERICA ..................................... 186
10.6 MIDDLE EAST & AFRICA .......... 189
10.6.1 GCC COUNTRIES ...... 194
10.6.2 SOUTH AFRICA ......... 197
10.6.3 REST OF MEA ........... 200
11 COMPETITIVE LANDSCAPE ................................... 205
11.1 INTRODUCTION ..................... 205
11.2 MARKET SHARE ANALYSIS, 2025 ......................................... 206
11.3 COMPETITOR DASHBOARD ....... 207
11.4 KEY DEVELOPMENTS ............ 208
12 COMPANY PROFILES ............................................. 210
12.1 BAYER AG .......................... 210
12.1.1 COMPANY OVERVIEW .......................................... 210
12.1.2 FINANCIAL OVERVIEW ......................................... 211
12.1.3 PRODUCTS OFFERED ........................................... 212
12.1.4 SWOT ANALYSIS ...... 212
12.1.5 KEY STRATEGIES ...... 213
12.2 MERCK KGAA ..................... 214
12.2.1 COMPANY OVERVIEW ......................................... 214
12.2.2 FINANCIAL OVERVIEW ......................................... 215
12.2.3 PRODUCTS OFFERED ........................................... 216
12.2.4 SWOT ANALYSIS ...... 216
12.2.5 KEY STRATEGIES ...... 217
12.3 PFIZER ............................... 218
12.3.1 COMPANY OVERVIEW .......................................... 218
12.3.2 PRODUCTS OFFERED ........................................... 219
12.3.3 SWOT ANALYSIS ...... 220
12.3.4 FINANCIAL ANALYSIS .......................................... 221
12.3.5 KEY STRATEGY ......... 221
12.4 RECKITT BENCKISER .............. 223
12.4.1 COMPANY OVERVIEW .......................................... 223
12.4.2 PRODUCTS OFFERED ........................................... 224
12.4.3 SWOT ANALYSIS ...... 224
12.4.4 FINANCIAL ANALYSIS .......................................... 225
12.4.5 KEY STRATEGY ......... 225
12.5 CHURCH & DWIGHT CO., INC. ............................................. 227
12.5.1 COMPANY OVERVIEW .......................................... 227
12.5.2 PRODUCTS OFFERED ........................................... 228
12.5.3 SWOT ANALYSIS ...... 229
12.5.4 FINANCIAL ANALYSIS .......................................... 230
12.5.5 KEY STRATEGY ......... 231
12.6 ABBVIE INC........................ 232
12.6.1 COMPANY OVERVIEW .......................................... 232
12.6.2 PRODUCTS OFFERED ........................................... 233
12.6.3 SWOT ANALYSIS ...... 233
12.6.4 FINANCIAL ANALYSIS .......................................... 234
12.6.5 KEY STRATEGY ......... 234
12.7 ORGANON & CO. .................. 236
12.7.1 COMPANY OVERVIEW .......................................... 236
12.7.2 PRODUCTS OFFERED ........................................... 237
12.7.3 SWOT ANALYSIS ...... 237
12.7.4 FINANCIAL ANALYSIS .......................................... 238
12.7.5 KEY STRATEGY ......... 239
12.8 MERCK & CO ...................... 240
12.8.1 COMPANY OVERVIEW .......................................... 240
12.8.2 PRODUCTS OFFERED ........................................... 241
12.8.3 SWOT ANALYSIS ...... 241
12.8.4 FINANCIAL ANALYSIS .......................................... 242
12.8.5 KEY STRATEGY ......... 242
12.9 FERRING PHARMACEUTICALS .............................................. 243
12.9.1 COMPANY OVERVIEW .......................................... 243
12.9.2 PRODUCTS OFFERED ........................................... 244
12.9.3 SWOT ANALYSIS ...... 244
12.9.4 FINANCIAL ANALYSIS .......................................... 245
12.9.5 KEY STRATEGY ......... 246
12.10 AMGEN ............................. 247
12.10.1 COMPANY OVERVIEW .......................................... 247
12.10.2 PRODUCTS OFFERED ........................................... 248
12.10.3 SWOT ANALYSIS ...... 248
12.10.4 FINANCIAL ANALYSIS .......................................... 249
13 DATA CITATIONS .......... 250

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 46
TABLE 2 PRODUCT PIPELINE 69
TABLE 3 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 79
TABLE 4 GLOBAL WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 80
TABLE 5 GLOBAL WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 80
TABLE 6 GLOBAL WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 80
TABLE 7 GLOBAL WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 81
TABLE 8 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 83
TABLE 9 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP, 2019-2035 (USD MILLION) 85
TABLE 10 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87
TABLE 11 GLOBAL WOMEN’S HEALTH MARKET, BY REGION, 2019-2035 (USD MILLION) 90
TABLE 12 NORTH AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 92
TABLE 13 NORTH AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 93
TABLE 14 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 93
TABLE 15 NORTH AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 94
TABLE 16 NORTH AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 94
TABLE 17 NORTH AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 94
TABLE 18 NORTH AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 95
TABLE 19 NORTH AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 95
TABLE 20 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 96
TABLE 21 US WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 97
TABLE 22 US WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 97
TABLE 23 US WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 98
TABLE 24 US WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 98
TABLE 25 US WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 98
TABLE 26 US WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 99
TABLE 27 US WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 99
TABLE 28 US WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 100
TABLE 29 CANADA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 101
TABLE 30 CANADA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 101
TABLE 31 CANADA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 102
TABLE 32 CANADA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 102
TABLE 33 CANADA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 102
TABLE 34 CANADA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 103
TABLE 35 CANADA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 103
TABLE 36 CANADA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 104
TABLE 37 EUROPE WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 106
TABLE 38 EUROPE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 107
TABLE 39 EUROPE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 107
TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 108
TABLE 41 EUROPE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 108
TABLE 42 EUROPE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 108
TABLE 43 EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 109
TABLE 44 EUROPE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 109
TABLE 45 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 110
TABLE 46 GERMANY WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 111
TABLE 47 GERMANY WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 111
TABLE 48 GERMANY WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 112
TABLE 49 GERMANY WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 112
TABLE 50 GERMANY WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 112
TABLE 51 GERMANY WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 113
TABLE 52 GERMANY WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 113
TABLE 53 GERMANY WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 114
TABLE 54 UK WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 115
TABLE 55 UK WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 115
TABLE 56 UK WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 116
TABLE 57 UK WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 116
TABLE 58 UK WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 116
TABLE 59 UK WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 117
TABLE 60 UK WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 117
TABLE 61 UK WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 118
TABLE 62 FRANCE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 119
TABLE 63 FRANCE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 119
TABLE 64 FRANCE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 120
TABLE 65 FRANCE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 120
TABLE 66 FRANCE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 120
TABLE 67 FRANCE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 121
TABLE 68 FRANCE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 121
TABLE 69 FRANCE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 122
TABLE 70 NETHERLANDS WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 123
TABLE 71 NETHERLANDS WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 123
TABLE 72 NETHERLANDS WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 124
TABLE 73 NETHERLANDS WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 124
TABLE 74 NETHERLANDS WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 124
TABLE 75 NETHERLANDS WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 125
TABLE 76 NETHERLANDS WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 125
TABLE 77 NETHERLANDS WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 126
TABLE 78 ITALY WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 127
TABLE 79 ITALY WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 127
TABLE 80 ITALY WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 128
TABLE 81 ITALY WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 128
TABLE 82 ITALY WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 128
TABLE 83 ITALY WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 129
TABLE 84 ITALY WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 129
TABLE 85 ITALY WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 130
TABLE 86 SPAIN WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 131
TABLE 87 SPAIN WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 131
TABLE 88 SPAIN WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 132
TABLE 89 SPAIN WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 132
TABLE 90 SPAIN WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 132
TABLE 91 SPAIN WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 133
TABLE 92 SPAIN WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 133
TABLE 93 SPAIN WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 134
TABLE 94 REST OF EUROPE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 135
TABLE 95 REST OF EUROPE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 135
TABLE 96 REST OF EUROPE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 136
TABLE 97 REST OF EUROPE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 136
TABLE 98 REST OF EUROPE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 136
TABLE 99 REST OF EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 137
TABLE 100 REST OF EUROPE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 137
TABLE 101 REST OF EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 138
TABLE 102 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 140
TABLE 103 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 141
TABLE 104 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 142
TABLE 105 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 142
TABLE 106 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 142
TABLE 107 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 143
TABLE 108 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 143
TABLE 109 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 143
TABLE 110 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 144
TABLE 111 CHINA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 145
TABLE 112 CHINA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 145
TABLE 113 CHINA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 146
TABLE 114 CHINA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 146
TABLE 115 CHINA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 146
TABLE 116 CHINA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 147
TABLE 117 CHINA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 147
TABLE 118 CHINA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 148
TABLE 119 INDIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 149
TABLE 120 INDIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 149
TABLE 121 INDIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 150
TABLE 122 INDIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 150
TABLE 123 INDIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 150
TABLE 124 INDIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 151
TABLE 125 INDIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 151
TABLE 126 INDIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 152
TABLE 127 JAPAN WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 153
TABLE 128 JAPAN WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 153
TABLE 129 JAPAN WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 153
TABLE 130 JAPAN WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 154
TABLE 131 JAPAN WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 154
TABLE 132 JAPAN WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 154
TABLE 133 JAPAN WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 155
TABLE 134 JAPAN WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 155
TABLE 135 SOUTH KOREA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 156
TABLE 136 SOUTH KOREA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 156
TABLE 137 SOUTH KOREA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 156
TABLE 138 SOUTH KOREA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 157
TABLE 139 SOUTH KOREA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 157
TABLE 140 SOUTH KOREA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 157
TABLE 141 SOUTH KOREA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 158
TABLE 142 SOUTH KOREA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 158
TABLE 143 MALAYSIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 159
TABLE 144 MALAYSIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 159
TABLE 145 MALAYSIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 159
TABLE 146 MALAYSIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 160
TABLE 147 MALAYSIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 160
TABLE 148 MALAYSIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 160
TABLE 149 MALAYSIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 161
TABLE 150 MALAYSIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 161
TABLE 151 THAILAND WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 162
TABLE 152 THAILAND WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 162
TABLE 153 THAILAND WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 162
TABLE 154 THAILAND WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 163
TABLE 155 THAILAND WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 163
TABLE 156 THAILAND WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 163
TABLE 157 THAILAND WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 164
TABLE 158 THAILAND WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 164
TABLE 159 INDONESIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 165
TABLE 160 INDONESIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 165
TABLE 161 INDONESIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 165
TABLE 162 INDONESIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 166
TABLE 163 INDONESIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 166
TABLE 164 INDONESIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 166
TABLE 165 INDONESIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 167
TABLE 166 INDONESIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 167
TABLE 167 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 168
TABLE 168 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 168
TABLE 169 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS,
2019-2035 (USD MILLION) 169
TABLE 170 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 169
TABLE 171 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 169
TABLE 172 REST OF REST OF EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 170
TABLE 173 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 170
TABLE 174 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 171
TABLE 175 LATIN AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 173
TABLE 176 LATIN AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 174
TABLE 177 LATIN AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 174
TABLE 178 LATIN AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 174
TABLE 179 LATIN AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 175
TABLE 180 LATIN AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 175
TABLE 181 LATIN AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 175
TABLE 182 LATIN AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 176
TABLE 183 LATIN AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 176
TABLE 184 BRAZIL WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 177
TABLE 185 BRAZIL WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 177
TABLE 186 BRAZIL WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 178
TABLE 187 BRAZIL WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 178
TABLE 188 BRAZIL WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 178
TABLE 189 BRAZIL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 179
TABLE 190 BRAZIL WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 179
TABLE 191 BRAZIL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 179
TABLE 192 MEXICO WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 180
TABLE 193 MEXICO WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 180
TABLE 194 MEXICO WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 180
TABLE 195 MEXICO WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 181
TABLE 196 MEXICO WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 181
TABLE 197 MEXICO WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 181
TABLE 198 MEXICO WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 182
TABLE 199 MEXICO WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 182
TABLE 200 ARGENTINA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 183
TABLE 201 ARGENTINA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 183
TABLE 202 ARGENTINA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 183
TABLE 203 ARGENTINA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 184
TABLE 204 ARGENTINA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 184
TABLE 205 ARGENTINA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 184
TABLE 206 ARGENTINA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 185
TABLE 207 ARGENTINA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 185
TABLE 208 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 186
TABLE 209 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 186
TABLE 210 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS,
2019-2035 (USD MILLION) 186
TABLE 211 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 187
TABLE 212 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 187
TABLE 213 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 187
TABLE 214 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 188
TABLE 215 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 188
TABLE 216 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 190
TABLE 217 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 191
TABLE 218 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 191
TABLE 219 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS,
2019-2035 (USD MILLION) 191
TABLE 220 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 192
TABLE 221 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 192
TABLE 222 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 192
TABLE 223 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 193
TABLE 224 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 193
TABLE 225 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 194
TABLE 226 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 194
TABLE 227 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 194
TABLE 228 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 195
TABLE 229 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 195
TABLE 230 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 195
TABLE 231 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 196
TABLE 232 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 196
TABLE 233 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 197
TABLE 234 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 197
TABLE 235 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 197
TABLE 236 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 198
TABLE 237 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 198
TABLE 238 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 198
TABLE 239 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 199
TABLE 240 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 199
TABLE 241 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 200
TABLE 242 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 200
TABLE 243 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS,
2019-2035 (USD MILLION) 201
TABLE 244 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS,
2019-2035 (USD MILLION) 201
TABLE 245 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 201
TABLE 246 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 202
TABLE 247 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 202
TABLE 248 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 203
TABLE 249 KEY DEVELOPMENTS: GLOBAL WOMEN’S HEALTH MARKET 208
TABLE 250 BAYER AG: PRODUCTS OFFERED 212
TABLE 251 MERCK KGAA.: PRODUCT OFFERED 216
TABLE 252 PFIZER: PRODUCT OFFERED 219
TABLE 253 RECKITT BENCKISER: PRODUCT OFFERED 224
TABLE 254 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERED 228
TABLE 255 ABBVIE INC.: PRODUCT OFFERED 233
TABLE 256 ORGANON & CO.: PRODUCT OFFERED 237
TABLE 257 MERCK & CO.: PRODUCT OFFERED 241
TABLE 258 FERRING PHARMACEUTICALS: PRODUCT OFFERED 244
TABLE 259 AMGEN: PRODUCT OFFERED 248